NCT07201727View on ClinicalTrials.gov

CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

May 1, 2028

Study Completion Date

July 1, 2028

Conditions
AML - Acute Myeloid Leukemia
Interventions
BIOLOGICAL

CD123+CLL-1 dual-target CAR-T cells sequential infusion CD7 CAR-T cells and bridging to allogeneic

For patients with refractory and relapsed AML, CD123+CLL-1 dual-target CAR-T cells (JY017) are used for treatment. Then, for patients who cannot achieve the minimum residual negative, CD7-targeted CAR-T cells (JY008) are sequentially infused. Finally, allogeneic hematopoietic stem cell transplantation is performed based on patient conditions.

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER